Abstract Background: Bone morphogenetic protein-9 (BMP-9), also known as Growth Differentiation Factor-2 (GDF-2), is a member of the TGF-β superfamily that has strong osteoinductive properties. Despite extensive investigation into BMPs for bone regeneration, BMP-9's unique receptor binding profile and exceptional osteogenic potency distinguish it from other family members, making it a promising candidate for enhancing osseointegration in dental implants. Objectives: This systematic review investigates the molecular signaling pathways of BMP-9, its alternative designations, preclinical and clinical evidence affirming its function in osseointegration, existing and novel delivery methods, and future prospects for its clinical application in implant dentistry. Methods: A thorough literature search was performed in the PubMed/MEDLINE, Scopus, Web of Science, Cochrane Library, and EMBASE databases from their inception to February 2026, adhering to PRISMA 2020 guidelines. The search terms utilized were "BMP-9," "GDF-2," "bone morphogenetic protein 9," "osseointegration," "dental implant," "osteogenesis," and "Smad signaling." Two reviewers looked at the studies separately. The inclusion criteria comprised in vitro, in vivo, and clinical studies assessing BMP-9 in relation to bone formation and implant integration. The risk of bias was evaluated utilizing suitable instruments for each category of study. Results: From an initial pool of 1,847 screened articles, 142 studies met the criteria for inclusion. BMP-9 communicates mostly through ALK1 and ALK2 receptors, which turn on both the canonical Smad1/5/8 and the non-canonical MAPK/PI3K pathways. Its enhanced osteogenic efficacy relative to BMP-2 and BMP-7 is due to varying receptor affinity and resilience against endogenous inhibitors like noggin and chordin. Preclinical data show that the volume of bone around the implant, the implant stability quotient (ISQ) values, and the speed of osseointegration all improve a lot. Hydrogels, nanoparticle carriers, and implant surface coatings are all promising ways to deliver drugs with controlled release profiles. Clinical translation is still limited, but early-phase trials show that it is safe and works in some cases. Conclusion: BMP-9 is a very powerful osteoinductive molecule with unique signaling properties that make it better than other BMPs for osseointegration. Continued improvement of delivery systems and dose-response characterization are necessary steps for dental implant therapy to be successful in clinical settings. Keywords: BMP-9; GDF-2; bone morphogenetic protein; osseointegration; dental implants; Smad signaling; osteogenesis; TGF-β superfamily; ALK1; bone regeneration.